Please wait a minute...
Reviews in Cardiovascular Medicine  2021, Vol. 22 Issue (3): 549-551     DOI: 10.31083/j.rcm2203065
Letter to the Editor Previous articles | Next articles
Impact of olokizumab on platelets, leukocytes and erythrocytes during mild COVID-19
Liudmila Buryachkovskaya1, Nikita Lomakin2, Arthur Melkumyants1, 3, Julia Docenko1, Victor Serebruany4, *()
1National Cardiology Research Center, 121552 Moscow, Russia
2Cardiology Division, Central Clinical Hospital of Presidential Administration, 121359 Moscow, Russia
3Institute of Physics and Technology, 141701 Moscow, Russia
4Neurology, Johns Hopkins University, Baltimore, MD 21794, USA
Download:  PDF(1836KB)  ( 141 ) Full text   ( 40 )
Export:  BibTeX | EndNote (RIS)      
Submitted:  31 August 2021      Revised:  02 September 2021      Accepted:  08 September 2021      Published:  24 September 2021     
Fund: 
19-015-00213/Russian Foundation for Basic Research
*Corresponding Author(s):  vserebr1@jhmi.edu; heartdrug@aol.com (Victor Serebruany)   

Cite this article: 

Liudmila Buryachkovskaya, Nikita Lomakin, Arthur Melkumyants, Julia Docenko, Victor Serebruany. Impact of olokizumab on platelets, leukocytes and erythrocytes during mild COVID-19. Reviews in Cardiovascular Medicine, 2021, 22(3): 549-551.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm2203065     OR     https://rcm.imrpress.com/EN/Y2021/V22/I3/549

No related articles found!
No Suggested Reading articles found!